Autosomal dominant polycystic kidney disease: Modifier genes and endothelial dysfunction

Nephrology Dialysis Transplantation

Volumn 18, Issue 11, 2003, Pages 2211-2215

  Devuyst, Olivier ^a   Persu, Alexandre ^a   Vo Cong, Minh Truc ^a  

^a UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

Author keywords

Endothelium; Modifying genes; Nitric oxide; Polycystic kidney disease; Polycystins

Indexed keywords

CHLORIDE CHANNEL; CHLORIDE ION; DIPEPTIDYL CARBOXYPEPTIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; POLYCYSTIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

CHROMOSOME 7Q; EDITORIAL; ENDOTHELIUM; ENVIRONMENTAL FACTOR; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HEREDITY; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ENDOTHELIUM, VASCULAR; HUMANS; MEMBRANE PROTEINS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROTEINS; TRPP CATION CHANNELS;

EID: 0242320334     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg351     Document Type: Editorial

References (38)

1. Pirson Y, Chauveau D, Grünfeld JP. Autosomal dominant polycystic kidney disease. In: Cameron JS, Davison AM, Grünfeld JP, Kerr DNS, Ritz E, eds. Oxford Textbook of Clinical Nephrology, 2nd edn. Oxford University Press, Oxford, UK; 1998: 2393-2415
2. Igarashi P, Somlo S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 2002; 13: 2384-2398
3. Peters DJM, Breuning MH. Autosomal dominant polycystic kidney disease: modification of disease progression. Lancet 2001; 358: 1439-1444
4. Hateboer N, van Dijk MA, Bogdanova N et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. Lancet 1999; 353: 103-107
5. Rossetti S, Burton S, Strmecki L et al. The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease. J Am Soc Nephrol 2002; 13: 1230-1237
6. Pei Y. A 'two-hit' model of cystogenesis in autosomal dominant polycystic kidney disease? Trends Mol Med 2001; 7: 151-156
7. Dipple KM, McCabe ER. Modifier genes convert 'simple' Mendelian disorders to complex traits. Mol Genet Metab 2000; 71: 43-50
8. Nadeau JH. Modifier genes in mice and humans. Nat Rev Genet 2001; 2: 165-174
9. Woo DD, Nguyen DK, Khatibi N, Olsen P. Genetic identification of two major modifier loci of polycystic kidney disease progression in pcy mice. J Clin Invest 1997; 100: 1934-1940
10. Kuida S, Beier DR. Genetic localization of interacting modifiers affecting severity in a murine model of polycystic kidney disease. Genome Res 2000; 10: 49-54
11. Wu G, Tian X, Nishimura S et al. Trans-heterozygous Pkd1 and Pkd2 mutations modify expression of polycystic kidney disease. Hum Mol Genet 2002; 11: 1845-1854
12. Levy M, Duyme M, Serbelloni P, Conte F, Sessa A, Grünfeld J-P. Is progression of renal involvement similar in twins with ADPKD? Contrib Nephrol 1995; 115: 65-71
13. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346
14. Baboolal K, Ravine D, Daniels J et al. Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease. Kidney Int 1997; 52: 607-613
15. Sullivan LP, Wallace DP, Grantham JJ. Epithelial transport in polycystic kidney disease. Physiol Rev 1998; 78: 1165-1191
16. O'Sullivan DA, Torres VE, Gabow PA, Thibodeau SN, King BF, Bergstralh EJ. Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. Am J Kidney Dis 1998; 32: 976-983
17. Persu A, Devuyst O, Lannoy N et al. CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000; 11: 2285-2296
18. Torres VE, Cai Y, Chen X et al. Vascular expression of polycystin-2. J Am Soc Nephrol 2001; 12: 1-9
19. Chauvet V, Qian F, Boute N et al. Expression of PKD1 and PKD2 transcripts and proteins in human embryo and during normal kidney development. Am J Pathol 2002; 160: 973-983
20. Kim K, Drummond I, Ibraghimov-Beskrovnaya O, Klinger K, Arnaout MA. Polycystin 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci USA 2000; 97: 1731-1736
21. Boulter C, Mulroy S, Webb S, Fleming S, Brindle K, Sandford R. Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene. Proc Natl Acad Sci USA 2001; 98: 12174-12179
22. Muto S, Aiba A, Saito Y et al. Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet 2002; 11: 1731-1742
23. Wang D, Iversen J, Strandgaard S. Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000; 11: 1371-1376
24. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012
25. Marsden PA, Heng HH, Scherer SW et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993; 268: 17478-17488
26. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-605
27. Zanchi A, Moczulski DK, Hanna LS, Wantman M, Warram JH, Krolewski AS. Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int 2000; 57: 405-413
28. Noiri E, Satoh H, Taguchi J et al. Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension 2002; 40: 535-540
29. Persu A, Stoenoiu MS, Messiaen T et al. Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 2002; 11: 229-241
30. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-1811
31. Fischmann TO, Hruza A, Niu XD et al. Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. Nat Struct Biol 1999; 6: 233-242
32. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 2000; 97: 2832-2835
33. Fairchild TA, Fulton D, Fontana JT, Gratton JP, McCabe TJ, Sessa WC. Acidic hydrolysis as a mechanism for the cleavage of the Glu(298)→Asp variant of human endothelial nitric-oxide synthase. J Biol Chem 2001; 276: 26674-26679
34. Walker D, Consugar M, Slezak J et al. The ENOS polymorphism is not associated with severity of renal disease in polycystic kidney disease 1. Am J Kidney Dis 2003; 41: 90-94
35. Devuyst O, Persu A, Stoenoiu MS, Lens X, Chauveau D, Pirson Y. ENOS polymorphism and renal disease progression in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2003; 41: 1124-1125
36. Boletta A, Qian F, Bhunia AK, Germino GG. PKD1-induced morphological changes in MDCK cells require PI3kinase. J Am Soc Nephrol 2002; 13: 105A
37. Luscher TF, Noll G. Is it all in the genes...? Nitric oxide synthase and coronary vasospasm. Circulation 1999; 99: 2855-2857
38. Ruschitzka F, Corti R, Noll G, Luscher TF. A rationale for treatment of endothelial dysfunction in hypertension. J Hypertens 1999; 17: S25-S35